Clinical trials: Multiple Myeloma Light Chain Induced Renal Insufficiency
Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
This study is a single-center, single-arm, open-label, Phase II interventional clinical trial designed to evaluate the efficacy and safety of a CM336 and isatuximab regimen in patients with newly diagnosed multiple myeloma (NDMM)…
- Trial name
- CAREMM-012 (NCT07585760)
- Testing
- CM336 Plus Isatuximab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Multiple Myeloma Light Chain Induced Renal Insufficiency
Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure
The purpose of this study is to determine efficacy of lenalidomide and dexamethasone in the treatment of patients with acute Myeloma (light chain)-induced renal failure.
- Trial name
- NCT00902915
- Testing
- lenalidomide plus dexamethasone
- Where
- 5 sites in Austria, Czechia
- Volunteers
- 50 people
- Sponsor
- Austrian Forum Against Cancer